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ABSTRACT
Objectives: Anaphylaxis is an important, potentially
life-threatening paediatric emergency. It is responsible
for considerable morbidity and, in some cases, death.
Poor outcomes may be associated with an inability to
differentiate between milder and potentially more
severe reactions and an associated reluctance to
administer self-injectable adrenaline. This study aims to
assess the effectiveness of a 24-h telephone access to
specialist paediatric allergy expert advice in improving
the quality of life of children and their families with
potentially life-threatening food allergy (ie, anaphylaxis)
compared with usual clinical care.
Methods and analysis: Children aged less than 16
years with food allergy and who carry an adrenaline
autoinjector will be recruited from the Paediatric Allergy
Clinic at Cork University Hospital, Ireland and baseline
disease-specific quality of life will be ascertained using
the validated Food Allergy Quality of Life Questionnaire
(FAQLQ). Participants will be randomised for a period of
6 months to the 24-h telephone specialist support line
or usual care. The primary outcome measure of interest
is a change in FAQLQ scores, which will be assessed at
0, 1 and 6 months postrandomisation. Analysis will be
on an intention-to-treat basis using a 2×3 repeated
measures within-between analysis of variance. Although
lacking power, we will in addition assess the impact of
the intervention on a range of relevant process and
clinical endpoints.
Ethics and dissemination: This trial protocol has
been approved by the Clinical Research Ethics Committee
of the Cork Teaching Hospitals. The findings will be
presented at international scientific conferences and will be
reported on in the peer-reviewed literature in early 2013.
INTRODUCTION
Anaphylaxis is an important, potentially life-
threatening paediatric emergency. Food is resp-
onsible for the majority of anaphylaxis cases in
the paediatric population.1 Egg, milk, peanuts
and tree nuts are the most common food
allergens in the preschool population; peanut
and tree nuts are the most common allergen
triggers in older children. There is a wide spec-
trum of allergic reactions to these allergens
ranging from minor urticarial reactions to ana-
phylaxis, with the associated risk of fatality.
Anaphylaxis is managed via a two-pronged
approach: ﬁrst lifestyle modiﬁcation to avoid
the allergen and second the acute manage-
ment of the anaphylactic event itself.2–4 Those
children who have had anaphylaxis, or who are
judged to be at high risk of anaphylaxis, are
ARTICLE SUMMARY
Article focus
▪ This study focuses on the emergency manage-
ment of children and young people with food
allergy triggered anaphylaxis.
Key messages
▪ Food allergy in children can have a significant
detrimental impact on the quality of life of both
the affected child and family members.
▪ Adrenaline is potentially life-saving, but has con-
sistently been found to be under-used in children
experiencing anaphylaxis.
▪ Access to 24-hour expert advice and support for
the emergency management of food triggered
reactions has the potential to provide reassur-
ance and improve clinical outcomes.
Strengths and limitations of this study
▪ The main strengths of the study include the fact
that this is one of the world’s first clinical trials
of the management of people with anaphylaxis,
the innovative intervention and the rigorous ran-
domised controlled trial design being employed.
▪ The main limitations are that we will not be
adequately powered to assess the impact of the
intervention on the hard clinical outcomes of
hospitalisation or mortality.
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prescribed adrenaline (epinephrine) autoinjectors.5 These
are to be carried on their person, or by their carers, at all
times in the case of accidental exposure to the allergen(s)
in question. This is important as, although uncommon
with an estimated incidence of one episode per 10 000 chil-
dren per year,5 most accidental exposures and subsequent
reactions tend to occur in community settings1 and
because of the typically rapid onset and progression of
reactions, most young people and their families do not
have immediate access to medical support when this is
most required.
Despite being prescribed an adrenaline autoinjector
and being shown the correct method of administration,
many young people and/or parents still often report
being unsure when to administer this treatment.6 7 They
often worry whether the reaction is severe enough to
warrant an injection of adrenaline or whether their
child may come to harm if given unnecessary treat-
ment.8 There is evidence that there is often a delay in
administering the prescribed medication in an emer-
gency.1 This delay in administering adrenaline may lead
to increased morbidity and also increases the risk of
fatality.9 10 Allergy services therefore often encourage
children and families/carers to use their autoinjectors
if there is any doubt regarding the severity of the aller-
gic reaction. Given the risk of further reactions and the
above-described concerns about when to administer
emergency treatment, it is perhaps unsurprising that
studies have found that food allergy can have a detri-
mental impact both on the children themselves and
also on family quality of life.11 12 There is, however, as
yet no clear evidence on how to improve clinical and/
or psychological outcomes in this population.
In the light of the above factors, we hypothesise that:
ﬁrst, uncertainty about the likely severity of their child’s
reaction (ranging from no reaction to mild to life-
threatening) on accidental re-exposure to the allergenic
food in question and second, what a patient or carer
must do if a reaction occurs, both contribute signiﬁ-
cantly to parental/child anxiety. We further hypothesise
that this uncertainty could be ameliorated by real-time
expert clinical guidance and support.
We propose therefore to test the effectiveness of giving
parents and carers of children and teenagers with
known food allergy, who are medically considered to be
at sufﬁcient risk of anaphylaxis that they have been pre-
scribed and trained in the use of adrenaline autoinjec-
tors, 24-h telephone access (intervention arm) or
ofﬁce-hour access (routine care arm) to expert advice
from the clinical allergy service. We will advise parents/
carers/teen patients randomised to the intervention
arm to ring this clinician-staffed advice line if they or
their child has an allergic reaction and they are unsure
as to how to manage it. We postulate that the availability
of this service will improve disease-speciﬁc quality of life
compared with families randomised to the routine care
arm who do not have this 24-h access. We also suspect
that the allergic reactions that parents or families
contact the allergy team about will be better managed as
a result of the advice given. There is currently no service
such as this available in Ireland or indeed worldwide.
This is, as far as we are aware, the ﬁrst ever randomised
clinical trial of patient care in the ﬁeld of anaphylaxis.13
AIMS AND OBJECTIVES
Aims
We seek to assess the effectiveness of 24-h telephone
access to specialist paediatric allergy expert advice in
improving the quality of life of children and their fam-
ilies with potentially life-threatening food allergy (ie,
anaphylaxis) compared with usual clinical care.
Main objective
To compare the difference in food allergy related
quality of life between the 24-h telephone access and
usual care at 1 and 6 months postrandomisation.
Secondary objectives
1. To compare the number and clinical severity of
incidents of suspected/conﬁrmed allergic reaction
in both groups.
2. To compare clinical and health service use out-
comes in both groups.
METHODS AND ANALYSIS
Design
We will undertake a pragmatic two-arm parallel group
randomised controlled trial.
Recruitment and consent
All families with food allergic children seen in the paedi-
atric allergy outpatient clinic at Cork University Hospital
will be informed about the study and invited to partici-
pate. A baseline-validated Food Allergy-speciﬁc
Quality-of-Life questionnaire (FAQL) will be completed
by interested family members in relation to each child
recruited.14–16 This FAQL questionnaire will be sent by
post to each family, with a stamp-addressed envelope.
Recruitment of families of children with food allergy
who carry an adrenaline autoinjector will occur in the
paediatric allergy out-patient clinic of Cork University
Hospital, which is the main centre for specialist paediat-
ric allergy service provision across Ireland. Notices with
information about the study will be placed around the
out-patient waiting rooms. A phone number with a 24-h
answering service will be advertised for families wishing
to obtain further information about the trial. Potentially
suitable patients will also be identiﬁed from the weekly
clinic preview team meetings.
All potentially interested parents will be given further
information about the study, and any questions they may
have will be answered. Children will, where appropriate on
the basis of their age and understanding, also be involved
in this discussion. Written informed consent will be
obtained from all parents/guardians wishing to take part
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in the trial. Those over the age of 8 years will also be asked
to sign an assent form in the presence of their parents.
Eligibility
Families of children satisfying the inclusion and exclu-
sion criteria detailed below will be eligible to participate
in the trial.
Inclusion criteria
1. Less than 16 years of age
2. Food allergy.
3. Previously prescribed an adrenaline autoinjector.
4. Carers and, where appropriate, children trained by
the clinical service how to use the prescribed
adrenaline autoinjector.
5. First eligible food allergic child in a family with
more than one eligible child.
Exclusion criteria
1. Awaiting food challenge and likely to undergo this
challenge during the trial period.
2. Experiencing another major life stressor during
timeline of trial, for example, changing school.
3. Second or subsequent eligible child in families
with more than one already recruited child.
Baseline assessment
All study participants will, as noted above, ﬁll out FAQL
questionnaires prior to randomisation. Parents will com-
plete the FAQL parent form (FAQL-PF) as a proxy for
their young children in those less than 13 years.
Children age 8–13 years will complete their own vali-
dated FAQL child form (FAQL-CF) and teenagers will
ﬁll in the FAQL teen form (FAQL-TF).
Randomisation
Randomisation will be undertaken only once all partici-
pants have been recruited, thereby minimising the risk
of any selection biases (that is, by maintaining alloca-
tion concealment). When all baseline questionnaires are
collected, the family will then be centrally randomised
by the be independently trial statistician, centrally
randomised in a 1 : 1 ratio, into the intervention (I) or
usual (U) care arms. All recruited families will thus sim-
ultaneously be allocated to the (I) or (U) arms, this
marking the onset of the trial period.
Intervention and control
The (I) group will be given a direct access mobile
phone number to ring in the event of a suspected
serious allergic reaction. This will be given on a
credit-card-sized document for ease of access in the
event of an emergency. The manning of this emergency
24-h helpline will be shared between experienced
members of the paediatric allergy team. In the event of
a suspected serious allergic reaction, the patient or
his/her parent or carer will be able to ring the on-call
trial clinician for advice. Trial staff will have a standard
incident report form (appendix 1) to keep record of
on-call encounters. It is to be ﬁlled out as soon as is
practical after the phone-call consultation. Their advice
will be tailored according to clinical need, but will
include instructions that there is either: (1) no need for
emergency treatment; (2) give antihistamines by mouth
and observe or (3) use the adrenaline autoinjector and
call an ambulance. The responding staff member will
keep a record of all such encounters and the advice
given. Consistency of advice given is ensured by each
staff member giving out previously agreed, standardised
instructions (appendix 1) and by a teleconference to be
had between all personnel, following all incidents where
advice is given on the 24-h helpline, to discuss the inci-
dent and ensure that the standardised advice was given.
Those allocated to the U care (control) arm will
receive standard care, with the option of contacting one
or more of the following: the Cork University Hospital
Paediatric Allergy team during working hours (Monday–
Friday 8:00–17:00), emergency/ambulance services,
their own registered general practitioner, out-of-hours
primary care providers or their nearest hospital emer-
gency departments.
The duration of trial period will be 6 months from the
point of randomisation.
Outcome measures
Primary
All study participants will complete the age-appropriate
(discussed above) validated FAQL at 1 and 6 months
post randomisation; speciﬁcally, any change from base-
line between intervention and control groups at the
1-month and 6-month assessment points.
The FAQLQ-PF, FAQLQ-CF and FAQLQ-TF are age
appropriate parent-administered, child self-administered
and teen self-administered questionnaires that measure
the impact of food allergy on health-related quality of life
(HRQL) of children of age 0–18 years. They were devel-
oped and validated under the auspices of EuroPrevall, a
European Commission-funded project with over 60 part-
ners (www.europrevall.org). We have previously demon-
strated good cross-sectional and longitudinal reliability
and validity in European and US samples. The question-
naire items are scored on a seven-point likert scale
ranging from 0 (no impact on HRQL) to 6 (extreme
impact on HRQL). The measures have three subscales
assessing general emotional impact; food anxiety; and
social and dietary limitations. The total score is calculated
as the mean of these three subscales.14–17
Secondary
Participants in both groups will also be asked to record
any possible allergic reactions that may have occurred,
which were self-managed and/or required medical
advice or attention other than provided through the
trial helpline. They will be provided with a standardised
form to record this information on (appendix 2). We
will record the clinical details of every reported event to
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include: incidence, severity, administration of adren-
aline, hospital attendance and death.
Statistical considerations
Analysis
We will assess the statistical signiﬁcance and relative
magnitude of changes over three time-points, that is, at
baseline (T0), 1 month (T1) and 6 months (T2) post-
randomisation, on the FAQL scores for both the (I) and
(U) care groups using a repeated measures 2×3 multi-
variate design.18 That is, the same case in either experi-
mental or control group (group factor), will complete
the questionnaires at three time-points (time factor).
The effect of the factors ‘time’ and ‘group’ on the total
score, and the interaction of these two factors, will be
analysed using a two-way within–between groups analysis
of variance (ANOVA). The interaction will address the
question; ‘Are the time proﬁles in terms of FAQL total
scores of the two groups (experimental/control) signiﬁ-
cantly different?’ If improvement over time is deter-
mined, a paired sample t test will be used to ascertain at
which time-point(s) the difference can be detected.
Secondary outcomes will be included in univariate and
multivariate models as independent and dependent vari-
ables and controls.
Independent t tests will be used to determine if there
are differences in magnitude of improvement in FAQL
scores for (I) vs (U) groups. The Bonferroni correction
method will be used to adjust for multiple comparisons.
We will calculate the responsiveness index (mean
change score/SD of change score), using Cohen’s change
index benchmarks; 0.2–0.4 (small), 0.5–0.7 (moderate)
and 0.81 (large).
We will assess the reliability of the change score by
computing the intraclass coefﬁcients of change in the
FAQLQ. The minimal important difference (MID) will
also be calculated. Because the validity of a retrospective
assessment of change has been questioned, we will deter-
mine the MID by computing the SE of measurement
(sp(1–r), using baseline FAQLQ scores as an ‘anchor’.
Missing data will be dealt with by the Multiple
Imputation method, which is suitable for ANOVA and
uses an imputation method with error built in.19
Analysis will be on an intention-to-treat basis by the
trial statistician who will be blinded to allocation. There
are no interim analyses planned.
Power
We will utilise a within/between repeated measures ana-
lysis of variance. An a priori total sample size required ×
power (1-β err prob), for a repeated measures within-
between ANOVA analysis is 16 in each group (interven-
tion/control) to yield a statistically signiﬁcant result at
>90% power with a 0.5 effect level.20
‘Within’ refers to expected differences between three
time periods (T0, T1 and T2) and ‘between’ refers to
expected differences between the intervention and
control groups (ﬁgure 1).
F tests: ANOVA: repeated measures, within-between
interaction
Analysis: A priori: compute required sample size
Input:
Effect size f=0.5
α err prob=0.05
Power (1-β err prob)=0.95
Number of groups=2
Repetitions=3
Corr among rep measures=0.4
Nonsphericity correction ɛ=1
Output:
Non-centrality parameter λ=20.000000
Critical F=3.340386
Numerator df=2.000000
Denominator df=28.000000
Group sample size=16
Actual power=0.973792 with an anticipated drop-out
rate of 20%, we therefore plan to recruit a total of
40 families.
ETHICS AND DISSEMINATION
Ethical approval has been obtained by the Clinical
Research Ethics Committee of the Cork Teaching
Hospitals (30 May 2011). All patients are aware that
their participation is voluntary and they may withdraw
from study at any time.
The principal investigator (PI) for the trial is Jonathan
Hourihane and he will lead the Trial Management
Group and he is responsible for the overall governance
and running of this trial. Other members of the Trial
Management Group are: Maeve Kelleher, John
Fitzsimons, Audrey DunnGalvin, Claire Cullinane and
Aziz Sheikh, and they will support the PI in delivering
this trial. Audrey DunnGalvin is the trial statistician.
We plan to report our ﬁndings at major national and
international scientiﬁc conferences. We also plan to
Figure 1 A priori total sample size required×power (1-β err
prob), for a repeated measures within-between analysis of
variance.
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publish our ﬁndings in the peer-reviewed literature. We
anticipate being in a position to report on ﬁndings in
early 2013.
Acknowledgements We are very grateful to the children and their families
who have agreed to participate in this trial.
Contributions JO'BH, AS and ADG conceived the idea for this trial, and this
was then further developed in association with MK and ADG. MK led the
drafting of this manuscript, which was critically commented on by all
coauthors.
Competing interests None.
Ethics approval Clinical Research Ethics Committee of the Cork Teaching
Hospitals.
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
1. De Silva SL, Mehr S, Tey D, et al. Paediatric anaphylaxis: a 5 year
retrospective review. Allergy 2008;63:1071–107.
2. Walker S, Sheikh A. Managing anaphylaxis: effective emergency and
long-term care are necessary. Clin Exp Allergy 2003;33:1015–18.
3. Soar J, Pumphrey R, Cant A, et al. Emergency treatment of anaphylactic
reactions—guidelines for healthcare providers. Working Group of the
Resuscitation Council (UK). Resuscitation 2008;77:157–69.
4. Simons FE, Ardusso LR, Bilò MB, et al. World Allergy Organization
anaphylaxis guidelines: summary. J Allergy Clin Immunol 2011;127:
587–93.e1-22.
5. Muraro A, Roberts G, Clark A, et al. The management of
anaphylaxis in childhood: position paper of the EAACI. Allergy
2007;62:857–71.
6. Gold MS, Sainsbury R. First aid anaphylaxis management in
children who were prescribed an epinephrine autoinjector device
(EpiPen). J Allergy Clin Immunol 2000;106:171–6.
7. Arkwright P, Farragher AJ. Factors determining the ability of parents
to effectively administer intramuscular adrenaline to food allergic
children. Pediatr Allergy Immunol 2006;17:227–9.
8. Kim S, Sincacore J, Pongracic J. Parental use of EpiPen for children
with food allergies. J Allergy Clin Immunol 2005;116:164–8.
9. Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal
anaphylactic reactions to food in children and adolescents. N Engl J
Med 1992;327:380–4.
10. Pumphrey RS. Lessons for management of anaphylaxis from a
study of fatal reactions. Clin Exp Allergy 2000;30:1144–50.
11. Sicherer S, Noone S, Munoz-Furlong A. The impact of childhood
food allergy on quality of life. Ann Asthma, Allergy Immunol
2001;87:461–4.
12. Avery N, King RM, Knight S, et al. Assessment of quality of life in
children with peanut allergy. Pediatr Allergy Immunol
2003;14:378–82.
13. Simons FE, Sheikh A. Evidence-based management of anaphylaxis.
Allergy 2007;62:827–9.
14. DunnGalvin A, Flokstra-de Blok BM, Burks AW, et al. Food
allergy QoL questionnaire for children aged 0–12 years: content,
construct, and cross-cultural validity. Clin Exp Allergy
2008;38:977–86.
15. Flokstra-de Blok BM, DunnGalvin A, Vlieg-Boerstra BJ, et al.
Development and validation of the self-administered Food Allergy
Quality of Life Questionnaire for Adolescents. J Allergy Clin Immunol
2008;122:139–44.e2.
16. Flokstra-de Blok BM , DunnGalvin A, Vlieg-Boerstra BJ, et al.
Development and validation of a self-administered Food Allergy
Quality of Life Questionnaire for children. Clin Exp Allergy
2009;39:127–37.
17. Hourihane JO’B, Chiang WC, Laubach SS, et al. Psychometric
validation of the FAQLQ-PF in a US sample of children with food
allergy. J Aller Clin Immunol 2008;121–2:1:S106–7.
18. Hinkelmann K, Kempthorne O. Design and analysis of experiments.
2008; I and II 2nd edn. Hoboken, NJ, USA: John Wiley & Sons, Inc.
doi: 10.1002/9780470191750.indauth
19. Graham JW. Missing data analysis: making it work in the real world.
Ann Rev Psychol 2009;60:549–76.
20. Cohen J. A power primer. Psychol Bull 1992;112:155–9.
APPENDIX 1
INCIDENT REPORT FORM
Patient name ____________________
Staff member name ___________________________________
Caller mother/father/patient/other ___________________________________
(Please specify)
Time of call (24 h) _ _: _ h
Patient location ___________________________________
Food suspected ___________________________________
How much eaten? ___________________________________
Time since ingestion ___________________________________
Asthma y/n ___________________________________
Current condition Advice to be given
Rash only Give antihistamine, do not use anapen yet
Rash and swelling Give antihistamine, do not use anapen yet
Cough/hoarseness Use anapen, call ambulance, go to hospital
Wheeze Use anapen, call ambulance, go to hospital
Dizzy/collapse Use anapen, call ambulance, go to hospital
Outcome (to be completed by
study team in Cork,
as soon as possible next working day)
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APPENDIX 2
Anaphylaxis 24-h helpline study
Record of any Food Allergy Reactions
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